| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2797843 | Diabetes Research and Clinical Practice | 2009 | 7 Pages |
AimsThe significance of hemoglobin A1C (HbA1C) on the survival of diabetic hemodialysis patients still remains controversial. We investigated the impact of HbA1C on the survival.MethodsA total of 122 diabetic patients on maintenance hemodialysis (age, 59.9 ± 11.9 years [mean ± SD]; hemodialysis duration: 53 ± 38 months) were surveyed (survey period: 46 ± 19 months).ResultsThe cumulative survival of the poor glycemic control group (mean HbA1C of 3-month period ≥6.3%, n = 62) was significantly lower than that of the good group (HbA1C < 6.3%, n = 60), as determined by Kaplan–Meier estimation (P = 0.0084, log-rank test). Kaplan–Meier analysis also demonstrated that both cardiovascular and non-cardiovascular mortalities were higher in the poor group than in the good group (P = 0.0545 and P = 0.0453, respectively). In a multivariate Cox proportional hazard model, the mean HbA1C was a significant predictor of survival (OR 1.260 per 1.0%, 95% CI 1.020–0.579, P = 0.0325).ConclusionsPoor glycemic control is an independent predictor of poor prognosis in diabetic hemodialysis patients. HbA1C is a clinically useful parameter for identifying the risk for mortality, both for cardiovascular and non-cardiovascular mortality, and that careful management of glycemic control by use of HbA1C is important.
